CPI(M) turns the heat on Keralam govt. over SMA drug controversy

The Communist Party of India (Marxist) raised strong objections to the Kerala government’s handling of the recent controversy surrounding the SMA drug used to treat spinal muscular atrophy, a rare genetic disorder. Critics argue that the state’s decision to allow a private firm to set the price of the medication has made it inaccessible to many families who depend on public health facilities. The controversy erupted after patients and advocacy groups reported that the cost of the drug had risen sharply, creating a barrier to treatment for a condition that already carries a heavy emotional and financial burden.

State secretary M.V. Govindan addressed a press conference in Thiruvananthapuram, stating that the government’s approach reflects a broader agenda of privatizing health services. He warned that handing over essential medicines to market forces could erode the principle of universal health care that Kerala has long championed. The party called for an immediate review of the pricing policy, greater transparency in procurement and a re‑affirmation of the state’s commitment to provide life‑saving drugs at affordable rates. Govindan urged the health minister to halt any further private contracts until a public consensus is reached.

The dispute matters to readers across Kerala because the state’s health model has been a source of pride and a benchmark for other Indian states. Any shift toward private pricing could set a precedent that influences how other rare‑disease treatments are supplied nationwide. Families affected by SMA fear that delayed or denied access to medication could worsen health outcomes, while the broader public worries about rising health costs. The outcome of this debate will shape the balance between market mechanisms and the state’s responsibility to safeguard public health.